© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Experts in breast oncology gather for a discussion on important datasets in breast cancer recently presented at the ESMO 2021 Virtual Meeting.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.
October 25th 2021
Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.
November 1st 2021
Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.
November 8th 2021
Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.
November 15th 2021
Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.